Charlotte Blessing is a Business Development & Alliance Manager with 5+ years of experience spanning both corporate and scientific positions in the  biotech industry. In her current role at Scenic Biotech, she identifies novel business opportunities and builds partnerships with global pharma to advance Scenic's innovate drug targets for neuro and metabolic diseases. With a background as a Scientist and Portfolio Manager, she brings a deep understanding of science to strategic business development. Charlotte holds a Ph.D. (with distinction) from Ludwig-Maximilians-University Munich, where she discovered a novel drug target that enhances the action of PARP inhibitors - a concept which she helped evolve into a biotech start-up and that is now being explored as a cancer drug in the clinic. At the BioBusiness Summer School, she will discuss what a discovery platform entails and how it can be used to build drug pipelines and effective business models in small biotech companies, such as Scenic.

About Scenic Biotech

Scenic Biotech is advancing modifier therapy, a radically new approach to treating genetic disorders. Instead of targeting the primary disease-causing mutation, modifier therapy seeks to rebalance health by acting on another function in the genome that can neutralize the disease impact, leading to a therapeutic effect. Our robust pipeline, derived from our proprietary Cell-seq platform, includes first-in-class small molecule programs that are either wholly owned or partnered through strategic collaborations with multinational pharmaceutical leaders. By unlocking new pathways in the genome, Scenic will develop a range of modifier therapies to help patients.